Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 5:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: VaxInnate Corporation Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Safety and Immunogenicity Study of VAX102 [Flagellin.HuM2e] Influenza Vaccine in Healthy Adults

NCT00603811
View directory record Official record
Conditions
Influenza Infection
Interventions
VAX102 [Flagellin.HuM2e], Placebo
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Lenexa, Kansas • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2014 · Synced Oct 4, 2026, 5:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of VAX125 Influenza Vaccine in Community-living Adults >= 65 Years of Age

NCT00966238
View directory record Official record
Conditions
Influenza
Interventions
VAX125
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
65 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
3
States / cities
Lanexa, Kansas • Rochester, New York • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2014 · Synced Oct 4, 2026, 5:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Safety and Immunogenicity Study in Healthy Adults of VAX125, a Recombinant HA-flagellin Influenza Vaccine

NCT00730457
View directory record Official record
Conditions
Influenza
Interventions
VAX125
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2014 · Synced Oct 4, 2026, 5:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Safety and Immunogenicity of VAX128A, VAC128B and VAX128C Novel H1N1 Influenza Vaccine in Healthy Adults

NCT01172054
View directory record Official record
Conditions
Influenza
Interventions
VAX128, Placebo
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Miami, Florida • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Oct 4, 2026, 5:53 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Safety Study of Recombinant Influenza Vaccine for Prevention

NCT02015494
View directory record Official record
Conditions
Influenza
Interventions
VAX2012Q
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 40 Years
Enrollment
316 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
4
States / cities
Lenexa, Kansas • Rochester, New York • Mt. Pleasant, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 4, 2026, 5:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of VAX102 Vaccine Given With Seasonal Flu Vaccine in Healthy Adults

NCT00921973
View directory record Official record
Conditions
Influenza
Interventions
VAX102, Placebo
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
Lenexa, Kansas • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 23, 2014 · Synced Oct 4, 2026, 5:53 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Study of the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (VAX2012Q) in Adults 18-64 Years

NCT02434276
View directory record Official record
Conditions
Influenza
Interventions
VAX2012Q, Fluzone Quadrivalent
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 64 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
6
States / cities
Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Oct 4, 2026, 5:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate the Immune Response to Two Doses of VAX102 Healthy Adults

NCT00921206
View directory record Official record
Conditions
Influenza
Interventions
VAX102
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 23, 2014 · Synced Oct 4, 2026, 5:53 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Comparative Safety and Immunogenicity of 1.0 µg Intramuscular (i.m.) and 2.0 µg Subcutaneous (s.c.) Dosing With VAX102 (M2e-flagellin) Universal Influenza Vaccine in Healthy Adults

NCT00921947
View directory record Official record
Conditions
Influenza
Interventions
VAX102
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 24, 2011 · Synced Oct 4, 2026, 5:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49

NCT01658800
View directory record Official record
Conditions
Influenza
Interventions
VAX161C vaccine
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
South Miami, Florida • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 4, 2026, 5:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years

NCT01560793
View directory record Official record
Conditions
Influenza
Interventions
VAX161 [STF2.HA5 H5N1]
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Miami, Florida • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2014 · Synced Oct 4, 2026, 5:53 PM EDT